Delving into the Latest Updates on Guangdong Zhaotai InVivo Biomedicine Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Guangdong Zhaotai InVivo Biomedicine Co., Ltd., a subsidiary of Hunan Zhaotai Medical Group Co., Ltd., was established in 2016 and is located in Guangzhou, Guangdong Province. It is mainly engaged in the research and development and clinical research of third and fourth generation CAR-T cell therapy technology for cancer treatment, which is fully owned with independent intellectual property rights.

Tags

Neoplasms

Respiratory Diseases

Digestive System Disorders

CAR-TILs

CAR-T

TIL therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	41
Nervous System Diseases	26

Top 5 Drug Type	Count

CAR-TILs	13
TIL therapy	13
CAR-T	13
CpG ODN	1
Natural Killer Cell Therapies	1

Top 5 Target	Count

CD276 x HPK1 x PD-1	3
GPC3 x HPK1 x PD-1	3
HPK1 x PD-1 x PSCA	3
HPK1 x Lewis-Y antigen x PD-1	3
AXL x HPK1 x PD-1	3

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Start Date01 Jan 2021

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

[+1]

NCT03882840

/ RecruitingPhase 1/2IIT

Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.

Start Date01 Jan 2019

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

[+1]

100 Clinical Results associated with Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Login to view more data

3

Literatures (Medical) associated with Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

01 Dec 2019·Journal of Hematology & Oncology

Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

Author: Weinkove, Robert ; He, Chang ; Geng, Suxia ; Chen, Dongmei ; Du, Xin ; Shao, Dan ; Huang, Lisi ; Jiang, Zhiwu ; Zhou, Maohua ; Qin, Le ; Huang, Xin ; Weng, Jianyu ; Deng, Chengxin ; Luo, Chenwei ; Wang, Yulian ; Zeng, Lingji ; Lai, Yunxin ; Chen, Xiaomei ; Tang, Zhaoyang ; Wu, Suijing ; Lai, Peilong ; Lu, Zesheng ; Li, Peng

The original article [1] contains an error in authorship whereby author, Robert Weinkove’s name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along with author’s updated affiliation.

01 Dec 2018·Journal of Hematology & OncologyQ1 · MEDICINE

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

Q1 · MEDICINE

ArticleOA

Author: He, Chang ; Robert, Weinkove ; Geng, Suxia ; Chen, Dongmei ; Du, Xin ; Shao, Dan ; Huang, Lisi ; Jiang, Zhiwu ; Zhou, Maohua ; Qin, Le ; Huang, Xin ; Weng, Jianyu ; Deng, Chengxin ; Luo, Chenwei ; Wang, Yulian ; Zeng, Lingji ; Lai, Yunxin ; Tang, Zhaoyang ; Wu, Suijing ; Lai, Peilong ; Chen, Xiaomei ; Lu, Zesheng ; Li, Peng

BACKGROUNDAnti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is limited due to poor responses and neurotoxicity. Here, we utilized a third generation of CAR T cell vector, which contains the Toll/interleukin-1 receptor (ITR) domain of Toll-like receptor 2 (TLR2), to generate 1928zT2 T cells targeting CD19, and evaluated the efficacy of 1928zT2 T cells in relapse or refractory B-ALL patients with extramedullary involvement.METHODS1928zT2 T cells were generated by 19-28z-TLR2 lentiviral vector transfection into primary human T lymphocytes. The anti-leukemia effect of 1928zT2 T cells were determined by killing assays and in xenografts. Three patients diagnosed as relapse or refractory ALL with extramedullary involvement were infused with 1928zT2 T cells, and the clinical responses were evaluated by BM smear, B-ultrasonography, PET/CT, histology, flow cytometry, qPCR, ELISA, and luminex assay.RESULTS1928zT2 T cells exhibited enhanced effector function against CD19+ leukemic cells in vitro and in a xenograft model of human extramedullary leukemia. Notably, the 1928zT2 T cells eradicated extramedullary leukemia and induced complete remission in the three relapse and refractory ALL patients without serious adverse effects. 1928zT2 T cells expanded robustly in the circulation of these three patients and were detected in the cerebrospinal fluid of patient 3. These three patients experienced cytokine release syndrome (CRS) with grade 2 or 3, which remitted spontaneously or after tocilizumab treatment. None of the three patients suffered neurotoxicity or needed further intensive care.CONCLUSIONSOur results demonstrate that 1928zT2 T cells with TLR2 incorporation augment anti-leukemic effects, particularly for eradicating extramedullary leukemia cells, and suggest that the infusion of 1928zT2 T cells is an encouraging treatment for relapsed/refractory ALL patients with extramedullary involvement.TRIAL REGISTRATIONClinicalTrials.gov identifier NCT02822326 . Date of registration: July 4, 2016.

01 Mar 2018·LeukemiaQ1 · MEDICINE

Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells

Q1 · MEDICINE

Article

Author: Li, B ; Li, P ; Wu, Q ; Yao, Y ; Lin, S ; Du, X ; Weng, J ; Wang, S ; Qin, L ; Zhao, R ; Liu, P ; Lai, Y ; Pei, D ; Jiang, Z ; Wei, X ; Tang, Z ; Lai, P

Chimeric antigen receptor (CAR) T-cell immunotherapies have shown unprecedented success in treating leukemia but limited clinical efficacy in solid tumors. Here, we generated 1928zT2 and m28zT2, targeting CD19 and mesothelin, respectively, by introducing the Toll/interleukin-1 receptor domain of Toll-like receptor 2 (TLR2) to 1928z and m28z. T cells expressing 1928zT2 or m28zT2 showed improved expansion, persistency and effector function against CD19⁺ leukemia or mesothelin⁺ solid tumors respectively in vitro and in vivo. In a patient with relapsed B-cell acute lymphoblastic leukemia, a single dose of 5 × 10⁴/kg 1928zT2 T cells resulted in robust expansion and leukemia eradication and led to complete remission. Hence, our results demonstrate that TLR2 signaling can contribute to the efficacy of CAR T cells. Further clinical trials are warranted to establish the safety and efficacy of this approach.

100 Deals associated with Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Login to view more data

100 Translational Medicine associated with Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

40

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Induced-T cell Like NK cells(Hunan Zhaotai Yongren Medical)	Neoplasms More	Phase 2 Clinical
AXL-CAR-TILs(Guangdong Zhaotai InVivo Biomedicine) ( AXL x HPK1 x PD-1 )	Colorectal Cancer More	Phase 1
GPC3-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine Co. Ltd.) ( GPC3 x HPK1 x PD-1 )	Advanced Hepatocellular Carcinoma More	Phase 1
MUC1-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine) ( HPK1 x MUC1 x PD-1 )	Lung Cancer More	Phase 1
Claudin 6-TILs(Guangdong Zhaotai InVivo Biomedicine) ( CLDN6 x HPK1 x PD-1 )	Colorectal Cancer More	Phase 1